Ramucirumab – A new hope for colorectal cancer patient

• Author Details:   
• Shikha Sharma
• Sandeep Sharma
• Rahul Kalotra
• DN Prasad

---

Metastatic colorectal cancer remains one of the deadliest types of cancer having significant presence globally. Exhaustive research throughout the scientific fraternities worldwide is now getting focused on selectively targeting the cancer cells. One such achievement has been the recent approval of ramucirumab by USFDA which has added to the existing armamentarium of angiogenesis inhibitors. Ramucirumab is a fully humanized monoclonal antibody directed against the extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2) which selectively inhibits the human VEGFR-2 with a much greater affinity than its natural ligands and can be used in the second-line treatment of metastatic colorectal cancer. The current review focuses on the details regarding ramucirumab, its journey from preclinical trial to clinical trial and the way forward.

Keywords: Colorectal Cancer, Monoclonal antibody, Vascular endothelial growth factor receptor 2, Ramucirumab